Baird reiterated an Outperform rating and $38.00 price target on Cempra, Inc. (NASDAQ: CEMP) following the company's second Phase 3 study of solithromycin.

Analyst Brian Skorney commented, "While the market is clearly reacting to potential signals about safety, we believe that the second Phase 3 study of solithromycin is completely consistent with the first Phase 3 outcome, supporting a US approval and European for community-acquired bacterial pneumonia (CABP)."

For an analyst ratings summary and ratings history on Cempra, Inc. click here. For more ratings news on Cempra, Inc. click here.

Shares of Cempra, Inc. closed at $19.29 yesterday.

Analyst Comments

Roth Capital Cuts Price Target on Cempra (CEMP) as Solithromycin Misses High Expectations October 19, 2015 8:53 AM Cempra to Report Third Quarter 2015 Financial ResultsOctober 19, 2015 8:02 AM Cempra to Report Third Quarter 2015 Financial ResultsOctober 19, 2015 8:01 AM SOLITAIRE-IV Data Not as Strong as ORAL; Leerink Partners Cuts Price Target on Cempra's (CEMP) to $21 October 16, 2015 1:13 PM Unusual 11 Mid-Day Movers 10/16: (YOKU) (SFXE) (YGE) Higher; (ZFGN) (CEMP) (PWR) LowerOctober 16, 2015 12:54 PM Pre-Open Stock Movers 10/16: (SFXE) (YOKU) (BOX) Higher; (ZFGN) (CEMP) (WYNN) LowerOctober 16, 2015 9:39 AM Cempra (CEMP) Announces Solitaire-IV Met All Endpoints in Phase 3October 16, 2015 7:01 AM Cempra Announces Positive Topline Phase 3 Clinical Results for Intravenous Solithromycin in the Treatment of Community-Acquired Bacterial PneumoniaOctober 16, 2015 7:00 AM Cempra Announces Positive Topline Phase 3 Clinical Results for Intravenous Solithromycin in the Treatment of Community-Acquired Bacterial PneumoniaOctober 16, 2015 7:00 AM